FOSUN PHARMA conducted multiple buybacks of H shares in December 2024, totaling 1,224,500 H shares as treasury shares. The buyback price range was from HKD 14.04 to HKD 14.36.Specifically, the company repurchased 306,000 shares, 185,500 shares, 204,500 shares, 350,000 shares, and 178,500 shares on December 9, 13, 27, 30, and 31 respectively. After the buyback, the number of issued H shares of the company (excluding treasury shares) decreased from 545,606,500 shares to 544,382,000 shares, while the number of treasury shares increased from 6,334,000 shares to 7,558,500 shares.As of December 31, 2024, FOSUN PHARMA's total share capital remained unchanged at 2,671,326,465 shares, which includes 551,940,500 H shares and 2,119,385,965 A shares. The company's A shares capital structure did not change during this month.

FOSUN PHARMA conducted multiple buybacks of H shares in December 2024, totaling 1,224,500 H shares as treasury shares. The buyback price range was from HKD 14.04 to HKD 14.36.Specifically, the company repurchased 306,000 shares, 185,500 shares, 204,500 shares, 350,000 shares, and 178,500 shares on December 9, 13, 27, 30, and 31 respectively. After the buyback, the number of issued H shares of the company (excluding treasury shares) decreased from 545,606,500 shares to 544,382,000 shares, while the number of treasury shares increased from 6,334,000 shares to 7,558,500 shares.As of December 31, 2024, FOSUN PHARMA's total share capital remained unchanged at 2,671,326,465 shares, which includes 551,940,500 H shares and 2,119,385,965 A shares. The company's A shares capital structure did not change during this month.